Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: Effects on areal and volumetric bone mineral density - The confors study

Journal of Bone and Mineral Research

Volumn 29, Issue 8, 2014, Pages 1777-1785

  Muschitz, Christian ^a   Kocijan, Roland ^a   Fahrleitner Pammer, Astrid ^b   Pavo, Imre ^c   Haschka, Judith ^a   Schima, Wolfgang ^d   Kapiotis, Stylianos ^e   Resch, Heinrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF SZEGED   (Hungary)

^d St Vincent Hospital Vienna   (Austria)

^e St Vincent Group   (Austria)

Author keywords

Anabolics; Antiresorptives; Bone QCT; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE[1-34]; PROCOLLAGEN TYPE I AMINOPROPEPTIDE; PROTEIN PRECURSOR; RALOXIFENE; UNCLASSIFIED DRUG; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; CROSS LINKING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OPEN STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPINE FRACTURE; TRABECULAR BONE; CLINICAL TRIAL; DRUG EFFECTS; MULTICENTER STUDY; OSTEOPOROSIS, POSTMENOPAUSAL; TIME; TREATMENT OUTCOME;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE HYDROCHLORIDE; TERIPARATIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904190480     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2216     Document Type: Article

References (38)

1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434-41.
2. Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab. 2005; 90: 3970-7.
3. Canalis E, Giustina A, Bilezikian JP., Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007; 357: 905-16.
4. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB., Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007; 22: 495-502.
5. Marcus R., Present at the beginning: a personal reminiscence on the history of teriparatide. Osteoporos Int. 2011; 22: 2241-8.
6. Marcus R, Wang O, Satterwhite J, Mitlak B., The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18: 18-23.
7. Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005; 20: 1507-13.
8. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000; 85: 2129-34.
9. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009; 24: 726-36.
10. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005; 353: 555-65.
11. Kurland ES, Heller SL, Diamond B, Cosman F, Bilezikian JP., The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int. 2004; 15: 992-7.
12. Cosman F, Keaveny TM, Kopperdahl D, et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. 2013; 28: 1328-36.
13. Cusano NE, Bilezikian JP., Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet. Curr Med Res Opin. 2011; 27: 1705-7.
14. Lewiecki EM., Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis ? Curr Med Res Opin. 2001; 27: 1493-7.
15. Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP., Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest. 2011; 34: 801-10.
16. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349: 1207-15.
17. Finkelstein JS, Wyland JJ, Lee H, Neer RM., Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010; 95: 1838-45.
18. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM., The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003; 349: 1216-26.
19. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005; 20: 1905-11.
20. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997; 350: 550-5.
21. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001; 16: 925-31.
22. Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011; 26: 503-11.
23. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008; 93: 3785-93.
24. Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009; 94: 3772-80.
25. Finkelstein JS, Wyland JJ, Leder BZ, et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab. 2009; 94: 2495-501.
26. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R., Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005; 353: 566-75.
27. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R., Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res. 2009; 24: 1110-5.
28. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013; 382: 50-6.
29. Leder BZ, Tsai JN, Uihlein AV, et al. Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women with Osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014 May; 99 (5): 1694-700.
30. Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H., Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res. 2013; 28: 196-205.
31. Girotra M, Rubin M, Bilezikian J., The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord. 2006; 7: 113-21.
32. Bilezikian JP., Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008; 6: 24-30.
33. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004; 164: 2024-30.
34. Adami S, San Martin J, Muñoz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)]treatment in postmenopausal women with osteoporosis. Osteoporos Int. 2008; 19: 87-94.
35. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004; 19: 1259-69.
36. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008; 93: 852-60.
37. Keel C, Kraenzlin ME, Kraenzlin CA, Müller B, Meier C., Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Miner Metab. 2010; 28: 68-76.
38. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; 23: 1591-600.